Sign in

Private company

Myovant Sciences Ltd.

American pharmaceutical preparations company, incorporated in California1

In its 2022 annual report the company says: “We are a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.”51 It is headquartered in London, United Kingdom.1

Last updated Oct 21, 2026.

Overview

$231.0MRevenue, fiscal 20222
-$206.0MNet income, fiscal 20222
  • IndustryPharmaceutical Preparations1
  • HeadquartersLondon, United Kingdom1
  • Incorporated inCA3
  • Business addressSuite 1, 3Rd Floor, 11-12 St. James Square, London, X0 Sw1Y 4Lb3
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-81.1%Operating margin2
-89.2%Net margin2
289.4%Revenue growth, 20222
-$269.5MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development28¢$107.4M
  • Selling, general and admin67¢$259.4M
  • Interest4¢$14.0M
  • Income tax1¢$5.0M

Out of $231.0M in revenue.2 The company lost money this year.

Financial statements

Revenue42$231.0M in 2022
0$100.0M$200.0M$300.0M2019: $0$020192020: $0$020202021: $59.3M$59.3M20212022: $231.0M$231.0M2022+289%
Operating income542-$187.3M in 2022+124% since 2017
-$300.0M-$200.0M-$100.0M02017: -$83.5M-$83.5M20172018: -$143.0M-$143.0M2018+71%2019: -$264.8M-$264.8M2019+85%2020: -$274.9M-$274.9M2020+4%2021: -$260.8M-$260.8M2021−5%2022: -$187.3M-$187.3M2022−28%
Net income5642-$206.0M in 2022+147% since 2017
-$300.0M-$200.0M-$100.0M02017: -$83.4M-$83.4M20172018: -$143.3M-$143.3M2018+72%2019: -$273.6M-$273.6M2019+91%2020: -$289.0M-$289.0M2020+6%2021: -$255.1M-$255.1M2021−12%2022: -$206.0M-$206.0M2022−19%
Fiscal year2016201720182019202020212022
Revenue$04$02$59.3M2$231.0M2
Research and development$43.5M5$116.8M6$222.6M4$192.6M2$136.7M2$107.4M2
Selling, general and admin$42.2M4$82.3M2$181.4M2$259.4M2
Operating income-$83.5M5-$143.0M5-$264.8M4-$274.9M2-$260.8M2-$187.3M2
Interest$05$2.0M5$8.8M4$12.7M2$10.4M2$14.0M2
Income before tax-$200.9M2
Income tax-$74.0K5$213.0K6$476.0K4$761.0K2$336.0K2$5.0M2
Net income-$83.4M5-$143.3M6-$273.6M4-$289.0M2-$255.1M2-$206.0M2
Earnings per share-$3.372-$2.832-$2.222
Earnings per share (diluted)-$3.372-$2.832-$2.222
Shares (weighted, basic)93.0M shares2
Shares (weighted, diluted)93.0M shares2

Compare Myovant Sciences Ltd. with another company

Corporate structure

Myovant Sciences Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Myovant Sciences Ltd.

  • Sumitomo Chemical Filed SC 13D/A on Myovant Sciences Ltd., latest Mar 10, 2023 (5 filings since Oct 27, 2021)
  • Alpine Global Management, LLC Filed SC 13G on Myovant Sciences Ltd., latest Feb 17, 2023
  • BB Biotech Filed SC 13G/A on Myovant Sciences Ltd., latest Feb 14, 2023 (2 filings since Feb 11, 2022)
  • FIL Ltd Filed SC 13G on Myovant Sciences Ltd., latest Feb 9, 2023
  • Janus Henderson Group Ltd. Filed SC 13G/A on Myovant Sciences Ltd., latest Feb 9, 2023 (2 filings since Feb 10, 2022)
  • Wellington Management Company Filed SC 13G/A on Myovant Sciences Ltd., latest Feb 6, 2023 (2 filings since Feb 4, 2022)
  • Myovant Sciences Ltd. London, United Kingdom

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Myovant Sciences Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$2.9M2 Mar 31, 2022$3.3M2 Mar 31, 2021−10.8%
Operating-lease assets (leased space)$8.0M2 Mar 31, 2022$9.7M2 Mar 31, 2021−17.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$406.7M2 Mar 31, 2022$674.5M2 Mar 31, 2021−39.7%
Marketable securities, current$27.5M2 Mar 31, 2022$10.4M2 Mar 31, 2021+163.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$7.6M2 Mar 31, 2022$2.6M2 Mar 31, 2021+190.5%
Raw materials$663.0K2 Mar 31, 2022$1.4M2 Mar 31, 2021−52.3%
Work in process$3.7M2 Mar 31, 2022$773.0K2 Mar 31, 2021+383.4%
Finished goods$3.2M2 Mar 31, 2022$448.0K2 Mar 31, 2021+610.7%

Leadership

Who has led Myovant Sciences Ltd., and when. Pick a name to see everywhere that person has worked.

Board members and other officers (23)

Timeline

  1. Mar 10, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights32
  2. Mar 1, 20238-K Shareholder vote33
  3. Jan 26, 20238-K Results of operations34
  4. Oct 26, 20228-K Results of operations35
  5. Oct 24, 20228-K Entered a material agreement; Other events36
  6. Oct 21, 20228-K Shareholder vote37
  7. Oct 3, 20228-K Other events38
  8. Jul 27, 20228-K Results of operations39
  9. May 10, 20228-K Results of operations40
  10. Mar 25, 20228-K Executive or director change41
  11. Jan 26, 20228-K Financial statements and exhibits42
  12. Jan 10, 20228-K Results of operations43

Calendar

When it reported results

  1. Jan 26, 2023Reported quarterly or annual results34
  2. Oct 26, 2022Reported quarterly or annual results35
  3. Jul 27, 2022Reported quarterly or annual results39
  4. May 10, 2022Reported quarterly or annual results40
  5. Jan 10, 2022Reported quarterly or annual results43
  6. Oct 26, 2021Reported quarterly or annual results44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

128 filings to the SEC since October 2021: 1 annual reports, 5 quarterly reports, 14 major events, 65 insider forms, 13 large holders, 30 other. The latest 20:

  1. Mar 20, 202315-12G EDGAR
  2. Mar 16, 2023EFFECT EDGAR
  3. Mar 16, 2023EFFECT EDGAR
  4. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  5. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  6. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  7. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  8. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  9. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  10. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  11. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  12. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  13. Mar 10, 20234 FORM 4 SUBMISSION EDGAR
  14. Mar 10, 2023SC 13D/A EDGAR
  15. Mar 10, 2023S-8 POS EDGAR
  16. Mar 10, 2023S-8 POS EDGAR
  17. Mar 10, 2023S-8 POS EDGAR
  18. Mar 10, 2023S-8 POS EDGAR
  19. Mar 10, 2023S-8 POS EDGAR
  20. Mar 10, 2023S-8 POS EDGAR

The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

38 open-market trades by officers, directors and large owners since October 2021: 1 buys and 37 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 10, 2023Sumitomo Chemical Co., Ltd.10% ownerBuy51,599,200$27.00$1.4BForm 4
Jan 18, 2023Lang MatthewGeneral Counsel & Corp. Secy.Sale1,272$26.89$34.2KForm 4
Jan 18, 2023Merendino LaurenChief Commercial OfficerSale2,008$26.89$54.0KForm 4
Jan 18, 2023Marek David CPrincipal Executive OfficerSale8,037$26.89$216.1KForm 4
Jan 18, 2023Arjona Ferreira Juan CamiloChief Medical OfficerSale1,109$26.89$29.8KForm 4
Jan 4, 2023Arjona Ferreira Juan CamiloChief Medical OfficerSale2,251$26.90$60.6KForm 4
Jan 4, 2023Lang MatthewGeneral Counsel & Corp. Secy.Sale2,779$26.90$74.8KForm 4
Dec 16, 2022Mehra UneekPrincipal Financial OfficerSale2,241$26.75$59.9KForm 4
Oct 18, 2022Merendino LaurenChief Commercial OfficerSale1,703$25.20$42.9KForm 4
Oct 18, 2022Marek David CPrincipal Executive OfficerSale11,156$25.20$281.1KForm 4
Oct 18, 2022Lang MatthewGeneral Counsel & Corp. Secy.Sale1,933$25.20$48.7KForm 4
Oct 18, 2022Arjona Ferreira Juan CamiloChief Medical OfficerSale1,604$25.20$40.4KForm 4
Oct 4, 2022Arjona Ferreira Juan CamiloChief Medical OfficerSale2,738$24.40$66.8KForm 4
Oct 4, 2022Lang MatthewGeneral Counsel & Corp. Secy.Sale3,679$24.40$89.8KForm 4
Sep 16, 2022Mehra UneekPrincipal Financial OfficerSale9,243$18.86$174.3KForm 4
Aug 15, 2022Lang MatthewGeneral Counsel & Corp. Secy.Sale31,214$18.23$569.0KForm 4
Jul 18, 2022Lang MatthewGeneral Counsel & Corp. Secy.Sale1,935$12.87$24.9KForm 4
Jul 18, 2022Merendino LaurenChief Commercial OfficerSale1,704$12.87$21.9KForm 4
Jul 18, 2022Marek David CPrincipal Executive OfficerSale11,164$12.87$143.7KForm 4
Jul 18, 2022Arjona Ferreira Juan CamiloChief Medical OfficerSale1,606$12.87$20.7KForm 4

All 38 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Myovant Sciences Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMyovant Sciences Ltd.1
  • CIK0001679082
  • Filer statusLarge accelerated filer1
  • Incorporated inCalifornia1
  • Fiscal year endsMarch 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business addressSuite 1, 3Rd Floor, 11-12 St. James Square, London, X0 SW1Y 4LB1
  • Phone44 207-400-33511
  • Shares outstanding97,235,316 as of Jan 20, 20238
  • Public float$963.4M as of Sep 30, 20212
  • On EDGAR sinceJul 11, 20161
  • Filings538 in all: 4 (245), 8-K (65), 3 (36), SC 13D/A (24), SC 13G/A (23), 10-Q (20), SC 13G (14), SC 13D (8)1
    All 48 form types

    DEF 14A (7), DEFA14A (7), S-8 (7), S-8 POS (7), 10-K (6), CORRESP (6), 424B5 (5), EFFECT (5), S-1/A (5), CT ORDER (4), SC 13E3/A (4), UPLOAD (4), POS AM (3), DEF 14C (2), DRS/A (2), DRSLTR (2), PRE 14C (2), S-3/A (2), SEC STAFF LETTER (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 4/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERTNYS (1), DEFM14A (1), DRS (1), FWP (1), POSASR (1), PRE 14A (1), PREM14A (1), PRER14A (1), S-1 (1), S-1MEF (1), S-3 (1), S-3ASR (1), SC 13E3 (1)

  • Latest filingsAnnual report (10-K) May 11, 2022
    Quarterly report (10-Q) Jan 26, 2023
    Proxy statement (DEF 14A) Jul 28, 2022
    Latest 8-K (8-K) Mar 10, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51